CN109071460B - 氨基苯并咪唑衍生物 - Google Patents

氨基苯并咪唑衍生物 Download PDF

Info

Publication number
CN109071460B
CN109071460B CN201680085289.9A CN201680085289A CN109071460B CN 109071460 B CN109071460 B CN 109071460B CN 201680085289 A CN201680085289 A CN 201680085289A CN 109071460 B CN109071460 B CN 109071460B
Authority
CN
China
Prior art keywords
pharmaceutical composition
cancer
compound
group
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680085289.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN109071460A (zh
Inventor
T·王
S·盖特利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translational Drug Development LLC
Original Assignee
Translational Drug Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Drug Development LLC filed Critical Translational Drug Development LLC
Publication of CN109071460A publication Critical patent/CN109071460A/zh
Application granted granted Critical
Publication of CN109071460B publication Critical patent/CN109071460B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680085289.9A 2016-03-02 2016-05-23 氨基苯并咪唑衍生物 Expired - Fee Related CN109071460B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302781P 2016-03-02 2016-03-02
US62/302,781 2016-03-02
PCT/US2016/033841 WO2017151165A1 (en) 2016-03-02 2016-05-23 Aminobenzimidazole derivatives

Publications (2)

Publication Number Publication Date
CN109071460A CN109071460A (zh) 2018-12-21
CN109071460B true CN109071460B (zh) 2022-08-09

Family

ID=59744272

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680085289.9A Expired - Fee Related CN109071460B (zh) 2016-03-02 2016-05-23 氨基苯并咪唑衍生物

Country Status (8)

Country Link
US (1) US20190040017A1 (cg-RX-API-DMAC7.html)
EP (1) EP3423439A4 (cg-RX-API-DMAC7.html)
JP (1) JP6768078B2 (cg-RX-API-DMAC7.html)
CN (1) CN109071460B (cg-RX-API-DMAC7.html)
AU (1) AU2016394945A1 (cg-RX-API-DMAC7.html)
CA (1) CA3053238A1 (cg-RX-API-DMAC7.html)
IL (1) IL261201B (cg-RX-API-DMAC7.html)
WO (1) WO2017151165A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105980365B (zh) 2014-02-11 2019-06-21 拜耳医药股份公司 作为mIDH1抑制剂的苯并咪唑-2-胺
PE20170143A1 (es) 2014-02-11 2017-03-19 Bayer Pharma AG Benzimidazol-2-aminas como inhibidores de midh1
US10780080B2 (en) * 2016-11-23 2020-09-22 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
US11236052B2 (en) * 2017-09-06 2022-02-01 Translational Drug Development, Llc Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase
EP4373811A4 (en) 2021-07-21 2025-05-21 Carna Biosciences, Inc. NEW 1,2-DIAMINOBENZIMIDAZOLE DERIVATIVE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107921126A (zh) * 2015-05-22 2018-04-17 转化药物开发有限责任公司 苯甲酰胺和活性化合物的组合物及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009528384A (ja) * 2006-03-02 2009-08-06 スミスクライン・ビーチャム・コーポレイション Ｐｉ３キナーゼ阻害剤として用いるためのチアゾロン
JP5868851B2 (ja) * 2009-06-23 2016-02-24 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート ベンズアミド誘導体
EP2715956B1 (en) * 2011-05-27 2019-09-11 Cisco Technology, Inc. Precision timing in a data over cable service interface specification (docsis) system
US20150297579A1 (en) * 2012-11-05 2015-10-22 Celgene Corporation Treatment of cancer with pomalidomide in a renally impaired subject
CN108026052B (zh) * 2015-07-16 2021-10-08 德国癌症研究公共权益基金会 作为mIDH1抑制剂的5-羟烷基苯并咪唑类

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107921126A (zh) * 2015-05-22 2018-04-17 转化药物开发有限责任公司 苯甲酰胺和活性化合物的组合物及其使用方法

Also Published As

Publication number Publication date
AU2016394945A1 (en) 2018-10-11
CN109071460A (zh) 2018-12-21
IL261201A (en) 2018-10-31
JP6768078B2 (ja) 2020-10-14
JP2019511485A (ja) 2019-04-25
WO2017151165A1 (en) 2017-09-08
US20190040017A1 (en) 2019-02-07
EP3423439A1 (en) 2019-01-09
CA3053238A1 (en) 2017-09-08
EP3423439A4 (en) 2019-08-14
IL261201B (en) 2022-01-01

Similar Documents

Publication Publication Date Title
CN104219954B (zh) 苯甲酰胺衍生物
US9381196B2 (en) Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
US9221773B2 (en) Benzamide derivatives
JP6768078B2 (ja) アミノベンゾイミダゾール誘導体
US11780816B2 (en) Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase
HK1260272A1 (en) Aminobenzimidazole derivatives
HK1260272B (en) Aminobenzimidazole derivatives
HK40026716A (en) Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase
HK1204227B (en) Benzamide derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1260272

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220809